Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4- [4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 818-826

  Chaki, Shigeyuki ^a   Hirota, Shiho ^a   Funakoshi, Takeo ^a   Suzuki, Yoshiko ^a   Suetake, Sayoko ^a   Okubo, Taketoshi ^a   Ishii, Takaaki ^a   Nakazato, Atsuro ^a   Okuyama, Shigeru ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (4 FLUOROPHENYL) 2 (4 ISOPROPYLPIPERIDIN 1 YL)ETHYL] 4 [4 (2 METHOXYNAPHTHALEN 1 YL)BUTYL]PIPERAZINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA INTERMEDIN; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DIAZEPAM; FLUVOXAMINE; HEXOBARBITAL; HORMONE RECEPTOR BLOCKING AGENT; MCL 0129; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; PIPERAZINE DERIVATIVE; SEROTONIN TRANSPORTER; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BINDING AFFINITY; CONDITIONING; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; ESCAPE BEHAVIOR; EXPLORATORY BEHAVIOR; HELPLESSNESS; HORMONE RECEPTOR INTERACTION; IMMOBILIZATION; LIGHT DARK CYCLE; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT; ROTATION; STRESS; SWIMMING; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BRAIN; CERCOPITHECUS AETHIOPS; COS CELLS; DARKNESS; ESCAPE REACTION; GUINEA PIGS; HAPLORHINI; HUMANS; LIGHTING; MALE; MICE; MICE, INBRED ICR; NAPHTHALENES; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, CORTICOTROPIN; STRESS;

EID: 0037310741     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044826     Document Type: Article

References (37)

1. Adan RA, Szklarczyk AW, Oosterom J, Brakkee JH, Nijenhuis WA, Schaaper WM, Meloen RH, and Gispen WH (1999) Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur J Pharmacol 378:249-258.
2. Blasquez C, Jegou S, Bunel DT, Delbende C, Braquet P, and Vaudry H (1991) Central-type benzodiazepines inhibit release of α-melanocyte-stimulating hormone from the rat hypothalamus. Neuroscience 42:509-516.
3. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, Deleon J, Heurich R, Licht-blau H, Shaposhnik Z, Daniewska I, Blackburn TP, et al. (2002) Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nature Med 8:825-830.
4. Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Bristow LJ, Flatman KL, Hutson PH, Kulagowski JJ, Leeson PD, Young L, and Tricklebank MD (1996) The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents. J Pharmacol Exp Ther 277:578-585.
6. Chaki S, Okuyama S, Nakazato A, Kumagai T, Okubo T, Ikeda Y, Oshida Y, Hamajima Y, and Tomisawa K (1999) In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001. Eur J Pharmacol 371:205-211.
7. Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ, and Cone RD (1997) Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 91:789-798.
8. Corda MG, Orlandi M, and Fratta W (1990) Proconflict effect of ACTH 1-24: interaction with benzodiazepines, Pharmacol Biochem Behav 36:631-634.
9. Cryan JF, Page ME, and Lucki I (2002) Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol 436:197-205.
10. De Barioglio SR, Lezcano N, and Celis ME (1991) Alpha MSH-induced excessive grooming behavior involves a GABAergic mechanism. Peptides 12:203-205.
11. Detke MJ and Lucki I (1996) Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav Brain Res 73:43-46.
12. Detke MJ, Rickels M, and Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121:66-72.
13. Dunn AJ, Green EJ, and Isaacson RL (1979) Intracerebral adrenocorticotropic hormone mediates novelty-induced grooming in the rat. Science (Wash DC) 203:281-283.
14. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz H, Northrop JP, Ringold GM, and Danielsen M (1987) Lipofectin: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84:7413-7417.
15. File SE and Clarke A (1980) Intraventricular ACTH reduces social interaction in male rats. Pharmacol Biochem Behav 12:711-715.
16. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzart G, Watson SJ, DelValle J, and Yamada T (1993) Molecular cloning of a novel melanocortin receptor. J Biol Chem 268:8246-8250.
17. Gantz I, Shimoto Y, Konda Y, Miwa H, Dickinson CJ, and Yamada T (1994) Molecular cloning, expression and characterization of a fifth melanocortin receptor. Biochem Biophys Res Commun 200:1214-1220.
18. Gonzalez MI, Vaziri S, and Wilson CA (1996) Behavioral effects of alpha-MSH and MCH after central administration in the female rat. Peptides 17:171-177.
19. Guimaraes FS, Carobrez AP, De Aguiar JC, and Graeff FG (1991) Anxiolytic effect in the elevated plus-maze of the NMDA receptor AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology 103:91-94.
20. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 89:131-141.
21. Kask A, Mutulis F, Muceniece R, Pahkla R, Mutule I, Wikberg JE, Rago L, and Schioth HB (1998) Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. Endocrinology 139:5006-5014.
22. Millan MJ, Dekeyne A, Papp M, La Rochelle CD, Macsweeny C, Peglion JL, and Brocco M (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters. II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J Pharmacol Exp Ther 298:581-591.
23. Millan MJ, Lejeune F, Gobert A, Brocco M, Auclair A, Bosc C, Rivet JM, Lacoste JM, Cordi A, and Dekeyne A (2000) S18616, a highly potent spiroimidazoline agonist at α2-adrenoceptors: II. Influence on monoaminergic transmission, motor function and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 295:1206-1222.
24. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, and Cone RD (1994) Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 8:1298-1308.
25. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T, and Tomisawa K (1999) Receptor binding, behavioral and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 289:926-935.
26. Owen MJ and Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473.
27. Panksepp J and Normansell L (1990) Effects of ACTH (1-24) and ACTH/MSH (4-10) on isolation-induced distress vocalization in domestic chicks. Peptides 11:915-919.
28. Pigott TA and Seay SM (1999) A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60:101-106.
29. Porsolt RD, Anton G, Blavet N, and Jalfre M (1978) Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379-391.
30. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, and Cone RD (1993) Identification of a receptor for γ melanocortin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 90:8856-8860.
31. 4 receptor selective MSH analogues. Br J Pharmacol 124:75-82.
32. Takamori K, Kawashima N, Chaki S, Nakazato A, and Kameo K (2001a) Involvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats. Life Sci 69:1241-1248.
33. Takamori K, Yoshida S, and Okuyama S (2001b) Repeated treatment with imipramine, fluvoxamine and tranylcypromine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test. Life Sci 69:1919-1926.
34. Vergoni AV, Bertolini A, Wikberg JE, and Schioth HB (1999) Selective melanocortin MC4 receptor blockage reduces immobilization stress-induced anorexia in rats. Eur J Pharmacol 369:11-15.
35. Von Frijtag JC, Croiset G, Gispen WH, Adan RA, and Wiegant VM (1998) The role of central melanocortin receptors in the activation of the hypothalamus-pituitary-adrenal-axis and the induction of excessive grooming. Br J Pharmacol 123:1503-1508.
36. Vrinten DH, Adan RAH, Groen GJ, and Gispen WH (2001) Chronic blockade of melanocortin receptors alleviates allodynia in rats with neuropathic pain. Anesth Analg 93:1572-1577.
37. Vrinten DH, Gispen WH, Groen GJ, and Adan RAH (2000) Antagonism of the melanocortin system reduces cold and mechanical allodynia in mononeuropathic rats. J Neurosci 20:8131-8137.